Minerva Neurosciences, Inc. Expected to Earn Q1 2025 Earnings of ($1.03) Per Share (NASDAQ:NERV)

Minerva Neurosciences, Inc. (NASDAQ:NERVFree Report) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Minerva Neurosciences in a research note issued to investors on Thursday, May 2nd. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of ($1.03) for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.92) EPS.

Minerva Neurosciences (NASDAQ:NERVGet Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.31).

Separately, StockNews.com upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Thursday.

Get Our Latest Stock Analysis on NERV

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $2.37 on Friday. The business has a 50-day simple moving average of $2.66 and a 200-day simple moving average of $5.30. The company has a market cap of $16.57 million, a PE ratio of -0.53 and a beta of 0.27. Minerva Neurosciences has a one year low of $2.29 and a one year high of $13.49.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Further Reading

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.